Temozolomide

Temozolomide

• CAS Number: 85622-93-1
• UNSPSC Description: Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].
• Target Antigen: Apoptosis; Autophagy; DNA Alkylator/Crosslinker
• Type: Reference compound
• Related Pathways: Apoptosis;Autophagy;Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Temozolomide.html
• Solubility: DMSO : 20.83 mg/mL (ultrasonic)|H2O : 2.86 mg/mL (ultrasonic)
• Smiles: O=C(C1=C(N2C=N1)N=NN(C)C2=O)N
• Molecular Weight: 194.154
• References & Citations: [1]Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4.|[2]Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131.|[3]Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10(12):1383-92.
• Shipping Conditions: Blue Ice
• Clinical Information: Launched